SP-MHCI-0845-3

Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

US$507.00

In stock

Description

About Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

The Human E3 ubiquitin-protein ligase RNF213 Peptide (IEDB: 605176) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The E3 ubiquitin-protein ligase Peptide, H-HRVYLVRKL-OH (Uniprot: Q63HN8 aa: 4275-4283) from JPT is produced under strict quality control and quality management.

Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL - Specifications

  • Peptide sequence: H-HRVYLVRKL-OH
  • Amount: 10 mg (10 x 1 mg)
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Breast cancer
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

References:
Read References with JPT’s Antigen Peptides
Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL has been described in:
Separate effects of the ankylosing spondylitis associated ERAP1 and ERAP2 aminopeptidases determine the influence of their combined phenotype on the HLA-B*27 peptidome., J Autoimmun, 2017 (PMID: 28063628)
A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens., Mol Cell Proteomics, 2017 (PMID: 27920218)

Documentation

Documentation for Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

Properties

Properties of Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Breast cancer
Layout: Freeze-dried in glass vial
Organism: Human
Protein Name: E3 ubiquitin-protein ligase
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Human E3 ubiquitin-protein ligase RNF213 4275-4283, HRVYLVRKL

Information Values
Sequence: H-HRVYLVRKL-OH
Specifications: 9mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote